Insulet Corporation
PODD Large CapHealthcare · Medical Devices
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Insulet Corporation en bref
Insulet Corporation (PODD) is currently trading at 127,20 € with a market capitalization of 8,8 Md €. The trailing P/E ratio stands at 34.06x, with a forward P/E of 18.04x. The 52-week range spans from 122,72 € to 309,70 €; the current price is 58.9% below the yearly high. Year-over-year revenue growth stands at +33.9%. The net profit margin stands at 10.44%.
💰 Dividende
Insulet Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
23 analystes évaluent Insulet Corporation (PODD) au consensus : Achat Fort. L'objectif de cours moyen est de 211,56 €, soit un potentiel de +66.32% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 143,99 € à 314,16 €.
Insulet Corporation : la thèse d'investissement en détail
Insulet Corporation (PODD) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 33.9% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 71.01%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 66.32% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The PEG ratio at 1.3 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
À surveiller
- The forward P/E of 18.04x is meaningfully below the trailing 34.06x — analysts expect earnings to step up; the next earnings release is the test.
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 66.32% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 33.9% sur un an
- Rentabilité élevée des capitaux propres (23% ROE)
- Marge brute élevée de 71.01% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Free cash flow positif
- –Actuellement jugée surévaluée
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to market-like volatility, elevated short interest (6.9%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Insulet Corporation?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news